- Home
- GSIW vs MYNZ Comparison
GSIW vs MYNZ Comparison
Compare GSIW & MYNZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GSIW
- MYNZ
- Stock Information
- Founded
- GSIW 2016
- MYNZ 2021
- Country
- GSIW Hong Kong
- MYNZ Germany
- Employees
- GSIW N/A
- MYNZ N/A
- Industry
- GSIW
- MYNZ Biotechnology: Pharmaceutical Preparations
- Sector
- GSIW
- MYNZ Health Care
- Exchange
- GSIW Nasdaq
- MYNZ Nasdaq
- Market Cap
- GSIW 8.3M
- MYNZ 7.2M
- IPO Year
- GSIW 2023
- MYNZ 2021
- Fundamental
- Price
- GSIW $0.40
- MYNZ $3.20
- Analyst Decision
- GSIW
- MYNZ Buy
- Analyst Count
- GSIW 0
- MYNZ 2
- Target Price
- GSIW N/A
- MYNZ $14.00
- AVG Volume (30 Days)
- GSIW 65.7K
- MYNZ 105.1K
- Earning Date
- GSIW 12-31-2024
- MYNZ 05-06-2025
- Dividend Yield
- GSIW N/A
- MYNZ N/A
- EPS Growth
- GSIW N/A
- MYNZ N/A
- EPS
- GSIW N/A
- MYNZ N/A
- Revenue
- GSIW $1,313,795.00
- MYNZ $893,991.00
- Revenue This Year
- GSIW N/A
- MYNZ $42.95
- Revenue Next Year
- GSIW N/A
- MYNZ N/A
- P/E Ratio
- GSIW N/A
- MYNZ N/A
- Revenue Growth
- GSIW N/A
- MYNZ N/A
- 52 Week Low
- GSIW $0.35
- MYNZ $0.18
- 52 Week High
- GSIW $12.30
- MYNZ $8.20
- Technical
- Relative Strength Index (RSI)
- GSIW 43.18
- MYNZ 40.90
- Support Level
- GSIW $0.35
- MYNZ $3.03
- Resistance Level
- GSIW $0.41
- MYNZ $3.31
- Average True Range (ATR)
- GSIW 0.04
- MYNZ 0.35
- MACD
- GSIW 0.00
- MYNZ 0.06
- Stochastic Oscillator
- GSIW 45.45
- MYNZ 61.80
About GSIW Garden Stage Limited
Garden Stage Ltd is a Hong Kong-based financial services provider principally engaged in the provision of placing and underwriting services; securities dealing and brokerage services; and asset management services. Its business is carried out through its wholly owned Operating Subsidiaries: a) I Win Securities, which is licensed to conduct Type 1 (dealing in securities) regulated activities under the SFO in Hong Kong, and b) I Win Asset Management, which is licensed to conduct Type 4 (advising on securities) and Type 9 (asset management) regulated activities under the SFO in Hong Kong.
About MYNZ Mainz Biomed N.V.
Mainz Biomed NV develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. The company's flagship product is ColoAlert, is an accurate, non-invasive and easy-to-use, early-detection diagnostic test for colorectal cancer based on real-time Polymerase Chain Reaction-based (PCR) multiplex detection of molecular-genetic biomarkers in stool samples. The company operates in one operating segment, genetic diagnostic testing.